Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease

PLoS One. 2013 Aug 12;8(8):e72291. doi: 10.1371/journal.pone.0072291. eCollection 2013.

Abstract

Acute coronary syndromes (ACS) may be triggered by acute infections. Systemic production of interferon gamma (IFN-γ) is induced during infection and regulates the production of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), both important in plaque stability. This study evaluates the effect of IFN-γ on the MMPs/TIMP-1 ratio in cultured monocytes from 30 patients with stable coronary artery disease (CAD), 30 with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI), and 30 healthy blood donors. Supernatant concentrations of MMP-1, -2, -9, and TIMP-1 were measured by enzyme-linked immunoassays. Basal concentration of MMP-1 and TIMP-1 was similar between groups, while MMP-2 was higher in healthy individuals and MMP-9 in patients with UA/NSTEMI. Upon IFN-γ stimulation, MMP-9 secretion increased in all groups, while TIMP-1 decreased only in patients with CAD, which in turn result in a strikingly elevation in their mean MMP-9/TIMP-1 ratio. MMP-1/TIMP-1 and MMP-2/TIMP-1 ratios were <1.0 in basal conditions and after stimulation in all groups. Our results suggest that nonstimulated monocytes from patients with stable CAD show a similar behavior than those from healthy individuals. However, stimulation with IFN-γ induces an increase on the MMP-9/TIMP-1 ratio as high as that found in patients with ACS. Thus, it may bring biological plausibility to the association between acute infections and the development of ACS.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / metabolism*
  • Female
  • Humans
  • Interferon-gamma / pharmacology*
  • Male
  • Matrix Metalloproteinase 9 / metabolism*
  • Middle Aged
  • Monocytes / drug effects*
  • Monocytes / metabolism*
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism*

Substances

  • Tissue Inhibitor of Metalloproteinase-1
  • Interferon-gamma
  • Matrix Metalloproteinase 9

Grants and funding

RS is in the Biomedical Research PhD Program at Universidad Nacional Autónoma de México (UNAM), and was recipient of a CONACyT scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.